Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis

Cognitive impairment (CI) is a critical feature for patients with childhood or juvenile multiple sclerosis (MS). To promote the understanding of CI and to address the impact of different pharmacological treatment strategies on cognitive performance in this patient group. A cohort of 19 patients with...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of paediatric neurology Vol. 23; no. 6; pp. 783 - 791
Main Authors:	Johnen, A., Elpers, C., Riepl, E., Landmeyer, N.C., Krämer, J., Polzer, P., Lohmann, H., Omran, H., Wiendl, H., Göbel, K., Meuth, S.G.
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.11.2019
Subjects:	Adjuvants, Immunologic - therapeutic use Adolescent Child Cognition Cognitive Dysfunction - etiology Cognitive Dysfunction - prevention & control Cohort Studies Disease-modifying drugs Executive Function - drug effects Female Humans Interferon beta-1a - therapeutic use Juvenile multiple sclerosis Male Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neuropsychological Tests Neuropsychology Paediatric multiple sclerosis Treatment Treatment Outcome Juvenile multiple sclerosis Cognition Treatment Neuropsychology Paediatric multiple sclerosis Disease-modifying drugs
ISSN:	1090-3798, 1532-2130, 1532-2130
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!